Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 15 hours agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 1 day agoLast month, MSD announced positive data from the Phase III STRIDE-10 trial of its investigational...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 4 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Cerevance receives milestone payment under Alzheimer's collaboration with Merck
Seeking Alpha· 17 hours agoPrivately held Cerevance receives milestone payment from Merck for Alzheimer's research...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 23 hours agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
FierceBiotech· 4 days agoFive months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market ...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 17 hours agoMeanwhile, Moderna is expanding its efforts in cancer treatment. The company is partnered with Merck...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 19 hours agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine...
Morningstar· 4 days agoThe trial evaluated the immunogenicity, tolerability and safety of V116 compared to PPSV23 (pneumococcal vaccine, polyvalent [23-valent]) in adults 50 years of age and older ...